Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 20/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 20/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827854 | 1.00 | OPRM1 (0.43) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL24833171 | 0.88 | OPRM1 (0.41) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL24828048 | 0.88 | OPRM1 (0.38) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL29316805 | 0.88 | OPRL1 (0.40) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL408516 | 0.87 | CHRNA7 (0.34) | — | |
| SCHEMBL25600510 | 0.85 | OPRL1 (0.39) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL24726517 | 0.85 | HRH3 (0.40) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL23384260 | 0.85 | HRH3 (0.40) | — | |
| SCHEMBL24585209 | 0.85 | OPRM1 (0.54) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL824131 | 0.84 | OPRL1 (0.49) | OPRM1OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | OPRM1 4485/4885OPRL1 2441/4885OPRK1 2307/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRM1 4706/4885OPRL1 4834/4885OPRK1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.